Condition: Advanced Hepatocellular Carcinoma · Sponsor: Zhejiang University
A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Qi Zhang, Associate professor · 13819137113 · qi.zhang@zju.edu.cn
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital, Medical College of Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
| the First Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06461624